Poland· PL-100485893

Apixaban Olpha

A apixaban product containing apixabanum, registered in Poland by Olpha AS. The same ATC class is registered in 17 of our 19 countries.

ATC B01AF02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedApixaban OlphaATCB01AF02REGISTER NO.PL-100485893PACKS LISTED5CHECKEDSeptember 27, 2026

Where it is registered

Apixaban is registered in 17 of 19 countries.

Countries holding a registration under ATC B01AF02 (apixaban), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Apixaban · ATC B01AF02

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apixaban costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $3.38 in France to $7.97 in Italy — a ×2.4 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Apixaban · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • IT Italy$7.97
  • CH Switzerland$4.70
  • FR France$3.38
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Apixabanum
Manufacturer
Olpha AS
Country
Poland (PL)
ATC code
B01AF02
ATC class
Apixaban
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

  • gtin
    04750258004720
  • gtin
    04750258004744
  • gtin
    04750258004713
  • gtin
    04750258004737
  • gtin
    04750258004706

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

398 interactions on record for apixaban.

Graded by severity as the source publishes them — 133 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Apixaban · interactions on record

398 records

  • 133 severe
  • 224 moderate
  • 2 minor

Most severe, free to view

  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe

39 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Apixaban in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All apixaban products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Abatixent, Apixaban +pharma
  • Belgium · Apixaban Ab, Apixaban Eg
  • Bulgaria · Abatixent, Apixaban
  • Cyprus · Abidalo, Apixaban
  • Czechia · Aboxoma, Apixaban
  • Germany · Abidalo, Akkirateron
  • Denmark · Apinovia, Apinovia 5 Mg Film-Coated Tablets
  • Estonia · Abatixent, Aboxoma
  • Spain · Apicassa, Apiclot
  • Finland · Apiclodem, Apixaban
  • France · Apixaban, Apixaban Aet
  • United Kingdom (Northern Ireland) · Apixaban, Apixaban Abdi
  • Greece · Abixatec, Aboxoma
  • Croatia · Abatixent, Abidalo
  • Hungary · Aboxoma, Apixaban
  • Ireland · Apixaban Abdi, Apixaban Aristo
  • Iceland · Apixaban Accord, Apixaban Krka
  • Italy · Apilion, Apixaban Abdi
  • Liechtenstein · Apixaban Accord, Eliquis
  • Lithuania · Abatixent, Aboxoma
  • Luxembourg · Apixaban Eg, Apixaban Ratiopharm
  • Latvia · Abatixent, Aboxoma
  • Malta · Abidalo, Antixara
  • Netherlands · Abatixent, Apilion
  • Norway · Apixaban Accord, Apixaban Axunio
  • Portugal · Apixaban Grindeks, Apixabano Alter
  • Romania · Abatixent, Aboxoma
  • Sweden · Apixaban, Apixaban Axunio
  • Slovenia · Abatixent, Aboxoma
  • Slovakia · Aboxoma, Apixaban

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e1a0da3d-a97e-45b8-b672-02bfb5b71cc7
GET /v1/drugs/e1a0da3d-a97e-45b8-b672-02bfb5b71cc7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "5 mg",
  "packaging": "04750258004720 ¦ Rp ¦ 158586\n56 tabl.\n04750258004744 ¦ Rp ¦ 158587\n168 tabl.\n04750258004713 ¦ Rp ¦ 158588\n28 tabl.\n04750258004737 ¦ Rp ¦ 158589\n60 tabl.\n04750258004706 ¦ Rp ¦ 158590\n200 tabl.",
  "substance": "Apixabanum 5 mg",
  "common_name": "Apixabanum",
  "pl_product_id": "100485893",
  "pozwolenie_nr": "29112",
  "auth_procedure": "DCP",
  "authorisation_validity": "2030-06-02"
}

See everything about apixaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.